Entera Bio (NASDAQ:ENTX) Trading Down 0.6% – Here’s What Happened

Shares of Entera Bio Ltd. (NASDAQ:ENTX) were down 0.6% during mid-day trading on Wednesday . The company traded as low as $1.45 and last traded at $1.54. 610,262 shares changed hands during trading, a decline of 78% from the average daily volume of 2,768,290 shares. The stock had previously closed at $1.55.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on ENTX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Entera Bio in a report on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating on shares of Entera Bio in a research note on Wednesday. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $9.00.

Entera Bio Stock Down 0.6%

The business’s 50-day moving average price is $1.24 and its 200 day moving average price is $1.41. The company has a market capitalization of $75.91 million, a P/E ratio of -5.70 and a beta of 1.56.

Entera Bio (NASDAQ:ENTX) last posted its earnings results on Friday, May 8th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. Analysts anticipate that Entera Bio Ltd. will post -0.34 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Superstring Capital Management LP bought a new position in shares of Entera Bio in the fourth quarter worth $33,000. Citadel Advisors LLC boosted its stake in Entera Bio by 243.0% during the third quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock valued at $77,000 after buying an additional 28,322 shares during the period. HighTower Advisors LLC grew its position in Entera Bio by 137.8% during the fourth quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock worth $84,000 after buying an additional 25,000 shares in the last quarter. Jane Street Group LLC grew its position in Entera Bio by 142.6% during the fourth quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock worth $144,000 after buying an additional 43,536 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in Entera Bio by 22.2% in the 4th quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock worth $210,000 after acquiring an additional 19,601 shares during the last quarter. Institutional investors own 14.11% of the company’s stock.

About Entera Bio

Entera Bio, Inc is a clinical?stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.